Article Information
PubMed
Published By
History
- Received June 24, 2021
- Revision received December 21, 2021
- Accepted December 21, 2021
- First published January 18, 2022.
- Version of record published March 2, 2022.
Copyright & Usage
Copyright © 2022 the authors SfN exclusive license.
Author Information
Author contributions
Author contributions: P.A. and J.P. designed research; P.A., M.H., A.B., M.P., J.S., and J.P. performed research; P.A., M.H., and A.B. analyzed data; P.A. wrote the first draft of the paper; P.A., M.H., A.B., and J.P. edited the paper; P.A. and J.P. wrote the paper.
Disclosures
- Received June 24, 2021.
- Revision received December 21, 2021.
- Accepted December 21, 2021.
This work was supported by the Grant Agency of the Czech Republic GACR 20-19136S and RVO67985823. We thank Katerina Kramerova for technical support and help with performing behavioral and immunohistochemical experiments.
The authors declare no competing financial interests.
- Correspondence should be addressed to Jiri Palecek at jiri.palecek{at}fgu.cas.cz
Funding
Grant Agency of the Czech Republic
GACR 20-19136SCzech Academy of Sciences
RVO67985823
Other Version
- previous version (January 18, 2022).
- You are viewing the most recent version of this article.
Online Impact
Article usage
In this issue
Dual PI3Kδ/γ Inhibitor Duvelisib Prevents Development of Neuropathic Pain in Model of Paclitaxel-Induced Peripheral Neuropathy
